Belite Bio

BLTE Rare disease Lead: NDA Submitted 3 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-31

Catalyst timeline

tinlarebant PDUFA date2027tinlarebant PDUFA date, 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Tinlarebant

tinlarebant · LBS-008

Small Molecule Target: RBP4

Stargardt Disease Type 1 NDA Submitted oral NCT05244304

tinlarebant

LBS-008

Small Molecule Target: RBP4

Geographic Atrophy Phase 3 oral NCT05949593

LBS-009

Small Molecule Target: RBP4

Non-Alcoholic Fatty Liver Disease Preclinical oral
Nonalcoholic Steatohepatitis Preclinical oral
Type 2 Diabetes Preclinical oral
Gout Preclinical oral

Biotech Distilled coverage (3)

2026-09-09 UPDATE: Belite Bio (BLTE) - A Second Flag on the Board 🔒 Paid
2026-08-12 UPDATE: Belite Bio (BLTE) - The Clock Is Set 🔒 Paid
2026-07-22 Belite Bio (BLTE) — Scientific Deep Dive for Tinlarebant (LBS-008) and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.